Corpus overview


MeSH Disease

Fever (221)

Coronavirus Infections (203)

Cough (163)

Disease (122)

Infections (102)

Human Phenotype

Fever (222)

Cough (162)

Fatigue (64)

Pneumonia (64)

Dyspnea (36)


    displaying 1 - 10 records in total 222
    records per page

    Descriptive epidemiology of 16,780 hospitalized COVID-19 patients in the United States

    Authors: Shemra Rizzo; Devika Chawla; Kelly Zalocusky; Daniel Keebler; Jenny Chia; Lisa Lindsay; Vincent Yau; Tripthi Kamath; Larry Tsai

    doi:10.1101/2020.07.17.20156265 Date: 2020-07-29 Source: medRxiv

    BACKGROUND: Despite the significant morbidity and mortality caused by the 2019 novel coronavirus disease MESHD (COVID-19), our understanding of basic disease MESHD epidemiology remains limited. This study aimed to describe key patient characteristics, comorbidities, treatments, and outcomes of a large U.S.-based cohort of patients hospitalized with COVD-19 using electronic health records (EHR). METHODS: We identified patients in the Optum De-identified COVID-19 EHR database who had laboratory-confirmed COVID-19 or a presumptive diagnosis between 20 February 2020 and 6 June 2020. We included hospitalizations that occurred 7 days prior to, or within 21 days after, COVID-19 diagnosis. Among hospitalized patients we describe the following: vital statistics and laboratory results on admission, relevant comorbidities (using diagnostic, procedural, and revenue codes), medications (NDC, HCPC codes), ventilation, intensive care unit (ICU) stay, length of stay (LOS), and mortality. RESULTS: We identified 76,819 patients diagnosed with COVID-19, 16,780 of whom met inclusion criteria for COVID-related hospitalization. Over half the cohort was over age TRANS 50 (74.5%), overweight MESHD overweight HP or obese (77.2%), or had hypertension MESHD hypertension HP (58.1%). At admission, 30.3% of patients presented with fever MESHD fever HP (>38C) and 32.3% had low oxygen saturation (<90%). Among the 16,099 patients with complete hospital records, we observed that 58.9% had hypoxia MESHD, 23.4% had an ICU stay during hospitalization, 18.1% were ventilated, and 16.2% died. The median LOS was 6 days (IQR: 4, 11). CONCLUSIONS: To our knowledge, this is the largest descriptive study of patients hospitalized with COVID-19 in the United States. We report summary statistics of key clinical outcomes that provide insights to better understand COVID-19 disease MESHD epidemiology.

    Clinical characteristics of neonates with coronavirus disease MESHD 2019 (COVID-19): a systematic review

    Authors: Yuan Hu; Jing Xiong; Yuan Shi

    doi:10.21203/ Date: 2020-07-29 Source: ResearchSquare

    This study aimed to summarize the existing literature on severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) infection in newborns to clarify the clinical features and outcomes of neonates with COVID-19. A systematic search was performed in PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Data, and VIP databases from January 1, 2019 to April 30, 2020. The references of relevant studies were also searched. A descriptive summary was organized by aspects of clinical presentations (symptoms, laboratory examinations, and imaging) and outcomes. We identified 14 studies reporting 18 newborns with COVID-19. The most common clinical manifestations were fever MESHD fever HP (62.5%), shortness of breath (50.0%), diarrhea MESHD diarrhea HP/ vomiting MESHD vomiting HP/feeding intolerance(43.8%), cough MESHD cough HP (37.5%), dyspnea MESHD dyspnea HP (25.0%), and nasal congestion/runny nose/ sneeze MESHD sneeze HP(25.0%). Atypical symptoms included jaundice MESHD jaundice HP and convulsion. Lymphocyte numbers decreased in 5 cases, and radiographic findings were likely to show pneumonia MESHD pneumonia HP. All newborns recovered and discharged from the hospital, and there was no death MESHD.Conclusion: Clinical symptoms of neonatal SARS-CoV-2 infection MESHD are atypical, most of them are mild. Up to now, the prognosis of newborns is good, and there is no death MESHD. Intrauterine vertical transmission TRANS is possible, but confirmed evidence is still lacking. The Long-term follow-up of potential influences of SARS-CoV-2 infection MESHD on neonates need further exploration.

    The Outcome of COVID-19 Patients with Acute Myocardial Infarction MESHD Myocardial Infarction HP

    Authors: Hassan Altamimi; Yasser Alahmad; Fadi Khazal; Mowahib Elhassan; Hajar AlBinali; Abdulrahman Arabi; Awad AlQahtani; Nidal Asaad; Mohammed Al-Hijji; Tahir Hamid; Ihsan Rafie; Ali S. Omrani; Saad AlKaabi; Abdullatif Alkhal; Muna AlMalslmani; Mohammed Ali; Murad Alkhani; Mariam AlNesf; Salem Abu Jalala; Salaheddine Arafa; Reem ElSousy; Omar AlTamimi; Ezzeldine Soaly; Charbel Abi khalil; Jassim Al Suwaidi

    doi:10.1101/2020.07.21.20156349 Date: 2020-07-27 Source: medRxiv

    Background Coronavirus Disease MESHD 2019 (COVID-19) is a rapidly expanding global pandemic resulting in significant morbidity and mortality. COVID-19 patients may present with acute myocardial infarction MESHD myocardial infarction HP (AMI). The aim of this study is to conduct detailed analysis on patients with AMI and COVID-19. Methods We included all patients admitted with AMI and actively known or found to be COVID-19 positive by PCR between the 4th February 2020 and the 11th June 2020 in the State of Qatar. Patients were divided into ST-elevation myocardial infarction MESHD myocardial infarction HP (STEMI) and Non-STE (NSTEMI). Results There were 68 patients (67 men and 1 woman) admitted between the 4th of February 2020 and the 11th of June 2020 with AMI and COVID-19. The mean age TRANS was 49.1, 46 patients had STEMI and 22 had NSTEMI. 38% had diabetes mellitus MESHD diabetes mellitus HP, 31% had hypertension MESHD hypertension HP, 16% were smokers, 13% had dyslipidemia, and 14.7% had prior cardiovascular disease MESHD. Chest pain MESHD Chest pain HP and dyspnea MESHD dyspnea HP were the presenting symptoms in 90% and 12% of patients respectively. Fever MESHD Fever HP (15%) and cough MESHD cough HP (15%) were the most common COVID-19 symptoms, while the majority had no viral symptoms. Thirty-nine (33 STEMI and 6 NSTEMI) patients underwent coronary angiography, 38 of them had significant coronary disease MESHD. Overall in-hospital MACE was low; 1 patient developed stroke MESHD stroke HP and 2 died. Conclusion Contrary to previous small reports, overall in-hospital adverse events were low in this largest cohort of COVID-19 patients presenting with AMI. We hypothesize patient profile including younger age TRANS contributed to these findings. Further studies are required to confirm this observation.

    COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19

    Authors: Garth W Strohbehn; Brian L Heiss; Sherin J Rouhani; Jonathan A Trujillo; Jovian Yu; Alec J Kacew; Emily F Higgs; Jeffrey C Bloodworth; Alexandra Cabanov; Rachel C Wright; Adriana Koziol; Alexandra Weiss; Keith Danahey; Theodore G Karrison; Cuoghi C Edens; Iazsmin Bauer Ventura; Natasha N Pettit; Bhakti Patel; Jennifer Pisano; Mary E Strek; Thomas F Gajewski; Mark J Ratain; Pankti D Reid

    doi:10.1101/2020.07.20.20157503 Date: 2020-07-26 Source: medRxiv

    Background Interleukin-6 (IL-6)-mediated hyperinflammation may contribute to the high mortality of coronavirus disease MESHD 2019 (Covid-19). Tocilizumab, an IL-6 receptor blocking monoclonal antibody SERO, has been repurposed for Covid-19, but prospective trials and dose-finding studies in Covid-19 are lacking. Methods We conducted a phase 2 trial of low-dose tocilizumab in hospitalized adult TRANS patients with Covid-19, radiographic pulmonary infiltrate HP, fever MESHD fever HP, and C-reactive protein (CRP) >= 40 mg/L who did not require mechanical ventilation. Dose cohorts were determined by a trial Operations Committee, stratified by CRP and epidemiologic risk factors. A range of doses from 40 to 200 mg (low-dose tocilizumab) was evaluated, with allowance for one repeat dose at 24-48 hours. The primary objective was to assess the relationship of dose to fever MESHD fever HP resolution and CRP response. Outcomes were compared with retrospective controls with Covid-19. Correlative studies evaluating host antibody SERO response were performed in parallel. Findings A total of 32 patients received low-dose tocilizumab. This cohort had improved fever MESHD fever HP resolution (75.0% vs. 34.2%, p = 0.001) and CRP decline (86.2% vs. 14.3%, p < 0.001) in the 24-48 hours following drug administration, as compared to the retrospective controls (N=41). The probabilities of fever MESHD fever HP resolution or CRP decline did not appear to be dose-related in this small study (p=0.80 and p=0.10, respectively). Within the 28-day follow-up, 5 (15.6%) patients died. For patients who recovered, median time to clinical recovery was 3 days (IQR, 2-5). Clinically presumed and/or cultured bacterial superinfections MESHD were reported in 5 (15.6%) patients. Correlative biological studies demonstrated that tocilizumab-treated patients produced anti- SARS-CoV-2 antibodies SERO comparable to controls. Interpretation Low-dose tocilizumab was associated with rapid improvement in clinical and laboratory measures of hyperinflammation in hospitalized patients with Covid-19. Results of this trial and its correlative biological studies provide rationale for a randomized, controlled trial of low-dose tocilizumab in Covid-19.

    Coronavirus Disease MESHD (COVID-19): Reviews, Applications, and Current Status

    Authors: Tanweer Alam

    id:10.20944/preprints202007.0641.v1 Date: 2020-07-26 Source:

    Currently, the COVID‐19 has directly affected the millions of humans lives. The symptoms of the disease MESHD involving fever MESHD fever HP, malaise, chest infection MESHD, and breathing difficulties, were identified, and its existence is continuously becoming restructured. The World Health Organization (WHO) had mentioned the wide diagnostics test besides COVID-19 that would also assist medical facilities to recognize infectious diseases as well MESHD as currently focusing efficiently on preventing and afterward defeating this viral disease MESHD. The infection MESHD is usually transmitted among human beings in direct contact, greatest through the liquid bubbles generated through cough MESHD cough HP, sneeze MESHD sneeze HP, or speaking. This paper reviews the COVID 19 pandemic, its history, current updates, contact tracing TRANS applications, and use of emerging technologies like the Internet of Things (IoT) and Blockchain for stopping the spreading and provide service online to the patient from a distance.

    A return to normal kidney function in a Caucasian male TRANS after COVID-19 induced dialysis-requiring kidney failure

    Authors: Peter Okholm MD; Jan Kampmann MD

    doi:10.21203/ Date: 2020-07-17 Source: ResearchSquare

    Background: Coronavirus disease MESHD 2019 also known as COVID-19 has been recognized by WHO as a global pandemic and has spread to most of the world. The disease MESHD has a multitude of clinical presentations, and especially the development of acute kidney injury MESHD acute kidney injury HP has been associated with increased mortality.Case Presentation: A 71-year old Caucasian male TRANS was admitted with fever MESHD fever HP and dyspnea MESHD dyspnea HP to the emergency MESHD department. His medical history included type 2 diabetes and hypertension MESHD hypertension HP. Blood SERO tests showed a normal kidney function before admission with a creatinine of 0,8 mg/dL. Clinical examination, blood SERO tests and Chest X-ray suggested COVID-19. At admission the diagnose COVID-19 was confirmed, fluid therapy was commenced and Angiotensin-converting enzyme therapy discontinued. The patients was intubated due to respiratory failures HP and transferred to the intensive care ward where he developed acute anuric kidney failure and was started in continuous renal replacement therapy. After 6 days of dialysis treatment his kidney function slowly started to improve, and he was discharged after 26 days of admission. 42 days after admission his creatinine was measured to 1.3 mg/dLConclusion: We present the rare case of a Caucasian male TRANS, who not only survived COVID-19 induced kidney failure that required continuous renal replacement therapy, but returned to almost baseline creatinine. We discuss the role of Angiotensin-converting enzyme inhibitor treatment in COVID-19 and the potential pathophysiological mechanism surrounding AKI in COVID-19 patients in literature, and connect it to our case report.

    Analysis of Clinical Imaging Characteristics of Patients with 2019-nCoV

    Authors: Hao Jiang; WEI GUO; Huijie Jiang; Ruoshui Zheng; Ziao Wang; Ru Yi; Baomin Su; Li Sun

    doi:10.21203/ Date: 2020-07-17 Source: ResearchSquare

    Background: This article retrospectively analyzed the clinical characteristics and CT characteristics of chest CT of 10 patients with coronavirus disease MESHD 2019 (COVID-19) diagnosed in Heilongjiang Province. Methods: A retrospective analysis of 10 COVID-19 patients confirmed by designated hospitals in Heilongjiang Province. Results: The clinical manifestations were mainly fever MESHD fever HP (80%) and cough MESHD cough HP (50%). Laboratory tests showed elevated C-reactive protein (70%) and serum SERO amyloid A (80%). CT mainly manifests as ground-glass opacity (100%) in the lung, more than two lung lobes (90%), and the lesions are mostly located in the right upper lobe (80%), and lobular septum thickening (60%) is common.Conclusions: In this group of patients with COVID-19, the typical CT manifestations are double lung sheet ground-glass opacity, which are mainly distributed in the subpleural area, and the range of involvement is more than or equal to two lung lobes, “paving stones” changes; pulmonary lesions were absorbed and fibrous cord foci were formed during the transition period. It is worth noting that hilum, mediastinal lymphadenopathy HP lymphadenopathy MESHD, and pleural effusion MESHD pleural effusion HP are less common. During the study period, follow-up imaging performed by some patients showed mild / moderate disease progression MESHD and gradually dissipating.

    Clinical Characteristics of 107 Patients with COVID-19 in Ningbo, China: Single Center Experience Outside Hubei

    Authors: Boming Wu; Junjie Li; Hongping Xuan; Nanhong Zheng; Honghua Ye; Yaoren Hu; Tong’en Chen; Hao Ying; Lingyan Fan; Qing Xie; Zike Sheng; Yin Ying

    doi:10.21203/ Date: 2020-07-17 Source: ResearchSquare

    Background Since December 2019, there has be an outbreak of coronavirus disease MESHD 2019 (COVID-19) caused by severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) in Wuhan, China. Nowadays, it rapidly spread across the country and then the worldwide. We aimed to investigate the clinical characteristics of patients with COVID-19.Methods The patients with confirmed COVID-19 admitted between January 25 and February 10, 2020, were enrolled. Epidemiological, demographic, clinical, laboratory, radiological data, and antivirus therapies, were retrospectively collected and analyzed. The 90-day follow-up of these patients was also performed.Results A total of 107 patients were included. The median age TRANS was 55.0 years (range from 18.0 to 85.0 years), and 72 (67.3%) were female TRANS. Ninety-three (86.9%) of the patients had a history of contacting with residents from Wuhan (n=31), or contacting with confirmed COVID-19 patients (n=62) within 2 weeks. Fifty-eight (54.2%) had a family cluster onset. Fever MESHD Fever HP and cough MESHD cough HP were the most common symptoms. Only two patients had diarrhea MESHD diarrhea HP. The most common underlying disease MESHD was hypertension MESHD hypertension HP. Lymphopenia MESHD Lymphopenia HP was observed in 26 patients. Fifty-two patients with an elevated level of IL-6. On admission, bilateral patchy shadowing and ground-glass opacity were the typical radiological findings on chest computed tomography. Six patients had an intensive care unit (ICU) stay. Antivirus therapy was performed to all patients. 105 patients discharged with an improved condition, and no death MESHD was occurred during our 90-day follow-up for these patients.Conclusions Patients with COVID-19 in our hospital had relatively mild symptoms, and good prognosis. This study also highlights the importance of human-to-human transmission TRANS in COVID-19.

    Does Endometriosis MESHD Endometriosis HP Increase Susceptibility to COVID–19 Infections MESHD? A case-control study in Women of Reproductive Age TRANS

    Authors: Bahram Moazzami; Shahla Chaichian; Saeed Samie; Masoumeh Majidi Zolbin; Fatemeh Jesmi; Meisam Akhlaghdoust; Mahin Ahmadi Pishkuhi; Zahra Sadat Mirshafiei; Fereshteh Khalilzadeh; Dorsa Safari

    doi:10.21203/ Date: 2020-07-17 Source: ResearchSquare

    Background: In today’s world, coronavirus disease MESHD 2019 (COVID–19) is the most critical health problem and research is continued on studying the associated factors. But it is not clear whether endometriosis MESHD endometriosis HP increases the risk of COVID–19.Methods: Women who referred to the gynecology clinic were evaluated and 507 women with endometriosis MESHD endometriosis HP (case group) were compared with 520 women without endometriosis MESHD endometriosis HP (control group). COVID–19 infection MESHD, symptoms, exposure, hospitalization, isolation, H1N1 infection MESHD and vaccination, and past medical history of the participants were recorded and compared between the groups using IBM SPSS Statistics for Windows version 21.Results: Comparison between the groups represent COVID–19 infection MESHD in 3.2% of the case group and 3% of the control group (P=.942). The control group had a higher frequency of asymptomatic infection MESHD asymptomatic TRANS (95.7% vs. 94.5%; P<.001) and fever MESHD fever HP (1.6% vs. 0%; P=.004), while the frequency of rare symptoms was more common in the case group (P<.001). The average disease MESHD period was 14 days in both groups (P=.694). COVID–19 infection MESHD was correlated with close contact TRANS (r=.331; P<.001 in the case group and r=.244; P<.001 in the control group), but not with the history of thyroid disorders, H1N1 vaccination, traveling TRANS to high-risk areas, and social isolation (P>.05).Conclusion: Endometriosis MESHD Endometriosis HP does not increase the susceptibility to COVID–19 infections MESHD, but alters the manifestation of the disease MESHD. The prevalence SERO of the disease MESHD may depend on the interaction between the virus and the individual’s immune system but further studies are required in this regard. 

    Early detection of COVID-19 pandemic: evidence from Baidu Index

    Authors: Bizhi Tu; Laifu Wei; Yaya Jia; Jun Qian

    doi:10.21203/ Date: 2020-07-16 Source: ResearchSquare

    Background: New coronavirus disease MESHD 2019 (COVID-19) poses a severe threat to human life, and causes a global pandemic. The purpose of current research is to explore the onset and progress of the pandemic with a novel perspective using Baidu Index.Methods: We collected the confirmed data of COVID-19 infection MESHD between January 11, 2020, and April 22, 2020, from the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Based on known literature, we obtained the search index values of the most common symptoms of COVID-19, including fever MESHD fever HP, cough MESHD cough HP, fatigue MESHD fatigue HP, sputum production, and shortness of breath. Spearman's correlation analysis was used to analyze the association between the Baidu index values for each COVID-19-related symptoms and the number of confirmed cases TRANS. Regional differences among 34 provinces/ regions were also analyzed. Results: Daily growth of confirmed cases TRANS and Baidu index values for each symptoms presented a robust positive correlation during the outbreak ( fever MESHD fever HP: rs=0.705, p=9.623×10-6; cough MESHD cough HP: rs=0.592, p=4.485×10-4; fatigue MESHD fatigue HP: rs=0.629, p=1.494×10-4; sputum production: rs=0.648, p=8.206×10-5; shortness of breath: rs=0.656, p=6.182×10-5). The average search-to-confirmed interval is 19.8 days in China ( fever MESHD fever HP: 22 days, cough MESHD cough HP: 19 days, fatigue MESHD fatigue HP: 20 days, sputum production: 19 days, and shortness of breath: 19 days). We discovered similar results in the top 10 provinces/regions, which had the highest cumulative cases. Conclusion: Search terms of COVID-19- related symptoms on the Baidu search engine can be used to early warn the outbreak of the epidemic. Relevant departments need to pay more attention to areas with high search index and take precautionary measures to prevent these potentially infected persons from spreading further. Baidu search engine can reflect the public's attention to the pandemic and regional epidemics of viruses. Based on changes in the Baidu index value, we can predict the arrival of the peak confirmed cases TRANS. The clinical characteristics related to COVID-19- including fever MESHD fever HP, cough MESHD cough HP, fatigue MESHD fatigue HP, shortness of breath, deserve more attention during the pandemic.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.